Patents Associated with High-Cost Drugs in Australia
نویسندگان
چکیده
منابع مشابه
Patents Associated with High-Cost Drugs in Australia
Australia, like most countries, faces high and rapidly-rising drug costs. There are longstanding concerns about pharmaceutical companies inappropriately extending their monopoly position by "evergreening" blockbuster drugs, through misuse of the patent system. There is, however, very little empirical information about this behaviour. We fill the gap by analysing all of the patents associated wi...
متن کاملqfd planning with cost consideration in fuzzy environment
در عصر حاضر که رقابت بین سازمان ها بسیار گسترش یافته است، مطالعه و طرحریزی سیستم های تولیدی و خدماتی به منظور بهینه سازی عملکرد آنها اجتناب ناپذیر می باشد. بخش عمده ای از رقابت پذیری سازمان ها نتیجه رضایتمندی مشتریان آنها است. میزان موفقیت سازمان های امروزی به تلاش آنها در جهت شناسایی خواسته ها و نیازهای مشتریان و ارضای این نیازها بستگی دارد. از طرفی کوتاه کردن زمان ارائه محصول/خدمات به مشتریان...
15 صفحه اولDecoding gene patents in Australia.
Patents directed to naturally occurring genetic material, such as DNA, RNA, chromosomes, and genes, in an isolated or purified form have been granted in Australia for many years. This review provides scientists with a summary of the gene patent debate from an Australian perspective and specifically reviews how the various levels of the legal system as they apply to patents-the Australian Patent...
متن کاملHigh cost of new drugs.
he investigation by The BMJ and Cambridge and Bath universities into the availability of breakthrough hepatitis C drugs raises important questions for NHS England about access to lifesaving drugs. But why are medicines so expensive in the first place? The pricing strategy of Gilead for sofosbuvir (Sovaldi) and ledipasvir-sofosbuvir (Harvoni) raises questions that go well beyond the UK. The BMJ'...
متن کاملAccess to high cost medicines in Australia: ethical perspectives
Access to "high cost medicines" through Australia's Pharmaceutical Benefits Scheme (PBS) is tightly regulated. It is inherently difficult to apply any criteria-based system of control in a way that provides a fair balance between efficient use of limited resources for community needs and equitable individual access to care. We suggest, in relation to very high cost medicines, that the present a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLoS ONE
سال: 2013
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0060812